We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
32 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Ravulizumab
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KANUMA sebelipase alfa rce 2 mg/mL injection intravenous infusion vial.
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STRENSIQ asfotase alfa rch 80 mg/0.80 ml injection solution vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STRENSIQ asfotase alfa rch 18 mg/0.45 ml solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STRENSIQ asfotase alfa rch 12 mg/0.30 ml solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STRENSIQ asfotase alfa rch 28 mg/0.70 ml solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STRENSIQ asfotase alfa rch 40 mg/1.00 ml solution for injection vial.